Thermo Fisher will acquire Patheon for approximately $7.2 billion, including the assumption of approximately $2 billion of net debt.
On May 15, 2017, Thermo Fisher Scientific announced plans to purchase Patheon for $35 per share in cash. The transaction totals approximately $7.2 billion, which includes the assumption of approximately $2 billion of net debt.
Patheon has a network of facilities, primarily in North America and Europe, and approximately 9000 professionals worldwide. In 2016, Patheon generated approximately $1.9 billion in revenue and will become part of Thermo Fisher's Laboratory Products and Services Segment, the companies said in a press release about the acquisition. The transaction is expected to be completed by the end of 2017.
“The combined company's extensive and deep relationships in the biopharma industry will enable significant cross-selling opportunities,” the companies noted in a statement. “For example, having biologics development and manufacturing capabilities as well as bioproduction technologies in one company will allow Thermo Fisher to offer a more comprehensive portfolio to gain share with these customers.”
Source: Thermo Fisher Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.